Updated Jul 16, 2026
Dorval Allison has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $87K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-16 | PBYI | PUMA BIOTECHNOLOGY, INC. | S — Open-market sale | 11.6K | $7.20 | $84K |
| 2026-06-16 | PBYI | PUMA BIOTECHNOLOGY, INC. | A — Grant or award | 27.0K | $0.00 | |
| 2025-07-25 | VERV | Verve Therapeutics, Inc. | J — Other acquisition / disposition | 13.3K | — | |
| 2024-12-03 | VERV | Verve Therapeutics, Inc. | S — Open-market sale | 555 | $5.64 | $3K |
| 2024-12-03 | VERV | Verve Therapeutics, Inc. | M — Option exercise | 1.9K | — |
Dorval Allison is a corporate insider — currently tracked as Director of PUMA BIOTECHNOLOGY, INC. (PBYI). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($87K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Dorval Allison profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.